Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Songmao Zheng, Sheri Moores, Stephen Jarantow, Jose Pardinas, Mark Chiu, Honghui Zhou & Weirong Wang. (2016) Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody. mAbs 8:3, pages 551-561.
Read now
Read now
Lihui Xu, Neeraj Kohli, Rachel Rennard, Yang Jiao, Maja Razlog, Kathy Zhang, Jason Baum, Bryan Johnson, Jian Tang, Birgit Schoeberl, Jonathan Fitzgerald, Ulrik Nielsen & Alexey A. Lugovskoy. (2013) Rapid optimization and prototyping for therapeutic antibody-like molecules. mAbs 5:2, pages 237-254.
Read now
Read now
Christian Klein, Claudio Sustmann, Markus Thomas, Kay Stubenrauch, Rebecca Croasdale, Jürgen Schanzer, Ulrich Brinkmann, Hubert Kettenberger, Jörg T. Regula & Wolfgang Schaefer. (2012) Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. mAbs 4:6, pages 653-663.
Read now
Read now
Johan Nilvebrant, D. Cameron Dunlop, Aroop Sircar, Thierry Wurch, Emilia Falkowska, Janice M. Reichert, Gustavo Helguera, Emily C. Piccione, Simon Brack & Sven Berger. (2012) IBC’s 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5–8, 2011, San Diego, CA. mAbs 4:2, pages 153-181.
Read now
Read now
Alexey A. Lugovskoy, Janice M. Reichert & Alain Beck. (2012) 7th Annual European Antibody Congress 2011. mAbs 4:2, pages 134-152.
Read now
Read now
Articles from other publishers (24)
Jackie Cheng, Meina Liang, Miguel F. Carvalho, Natalie Tigue, Raffaella Faggioni, Lorin K. Roskos & Inna Vainshtein. (2020) Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody. Antibodies 9:3, pages 49.
Crossref
Crossref
Carolina Attallah, María Fernanda Aguilar, Guillermina Forno, Marina Etcheverrigaray, Marcelo De Macedo Brigido, Andrea Queiroz Maranhão & Marcos Oggero. (2020) The glycosylation of anti-rhIFN-α2b recombinant antibodies influences the antigen-neutralizing activity. Biotechnology Letters 42:8, pages 1369-1381.
Crossref
Crossref
Nitya S. Ramadoss, Nancy Q. Zhao, Barbra A. Richardson, Philip M. Grant, Peter S. Kim & Catherine A. Blish. (2020) Enhancing natural killer cell function with gp41-targeting bispecific antibodies to combat HIV infection. AIDS Publish Ahead of Print.
Crossref
Crossref
Adam J. Camblin, Gege Tan, Michael D. Curley, Isabel Yannatos, Sergio Iadevaia, Victoria Rimkunas, Mari Mino-Kenudson, Troy Bloom, Birgit Schoeberl, Daryl C. Drummond, Alexey A. Lugovskoy, Chrystal U. Louis & Vasileios Askoxylakis. (2019) Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Scientific Reports 9:1.
Crossref
Crossref
Ignacio Asial, Pär Nordlund & Sue-Li Dahlroth. 2019. High-Throughput Protein Production and Purification. High-Throughput Protein Production and Purification
299
320
.
Adam J. Camblin, Emily A. Pace, Sharlene Adams, Michael D. Curley, Victoria Rimkunas, Lin Nie, Gege Tan, Troy Bloom, Sergio Iadevaia, Jason Baum, Charlene Minx, Akos Czibere, Chrystal U. Louis, Daryl C. Drummond, Ulrik B. Nielsen, Birgit Schoeberl, J. Marc Pipas, Robert M. Straubinger, Vasileios Askoxylakis & Alexey A. Lugovskoy. (2018) Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Clinical Cancer Research 24:12, pages 2873-2885.
Crossref
Crossref
A. A. Lugovskoy. (2017) Engineering Antibodies as Drugs: Principles and Practice. Molecular Biology 51:6, pages 772-781.
Crossref
Crossref
Yariv Mazor, Kris F. Sachsenmeier, Chunning Yang, Anna Hansen, Jessica Filderman, Kathy Mulgrew, Herren Wu & William F. Dall’Acqua. (2017) Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Scientific Reports 7:1.
Crossref
Crossref
Joachim Koch & Michael Tesar. (2017) Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy. Transfusion Medicine and Hemotherapy 44:5, pages 337-350.
Crossref
Crossref
James R. Kintzing, Maria V. Filsinger Interrante & Jennifer R. Cochran. (2016) Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment. Trends in Pharmacological Sciences 37:12, pages 993-1008.
Crossref
Crossref
Bryan M. Dunyak, Robert L. Nakamura, Alan D. Frankel & Jason E. Gestwicki. (2015) Selective Targeting of Cells via Bispecific Molecules That Exploit Coexpression of Two Intracellular Proteins. ACS Chemical Biology 10:11, pages 2441-2447.
Crossref
Crossref
Alexey A. Lugovskoy & Melissa L. Geddie. 2015. Biobetters. Biobetters
203
220
.
Ana Blanco-Toribio, Javier Lacadena, Natalia Nuñez-Prado, Ana Álvarez-Cienfuegos, Maider Villate, Marta Compte, Laura Sanz, Francisco J Blanco & Luis Álvarez-Vallina. (2014) Efficient production of single-chain fragment variable-based N-terminal trimerbodies in Pichia pastoris. Microbial Cell Factories 13:1.
Crossref
Crossref
Jonathan B. Fitzgerald, Bryan W. Johnson, Jason Baum, Sharlene Adams, Sergio Iadevaia, Jian Tang, Victoria Rimkunas, Lihui Xu, Neeraj Kohli, Rachel Rennard, Maja Razlog, Yang Jiao, Brian D. Harms, Kenneth J. OlivierJrJr, Birgit Schoeberl, Ulrik B. Nielsen & Alexey A. Lugovskoy. (2014) MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors. Molecular Cancer Therapeutics 13:2, pages 410-425.
Crossref
Crossref
Brian D. Harms, Jeffrey D. Kearns, Sergio Iadevaia & Alexey A. Lugovskoy. (2014) Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies. Methods 65:1, pages 95-104.
Crossref
Crossref
Roy Jefferis. 2014. Antibody Fc. Antibody Fc
297
316
.
Cassie J. Liu & Jennifer R. Cochran. 2014. Engineering in Translational Medicine. Engineering in Translational Medicine
365
396
.
Chengzao Sun, James L. Trevaskis, Carolyn M. Jodka, Swetha Neravetla, Pete Griffin, Kui Xu, Yan Wang, David G. Parkes, Bruce Forood & Soumitra S. Ghosh. (2013) Bifunctional PEGylated Exenatide-Amylinomimetic Hybrids to Treat Metabolic Disorders: An Example of Long-Acting Dual Hormonal Therapeutics. Journal of Medicinal Chemistry 56:22, pages 9328-9341.
Crossref
Crossref
DC Kirouac & MD Onsum. (2013) Using Network Biology to Bridge Pharmacokinetics and Pharmacodynamics in Oncology. CPT: Pharmacometrics & Systems Pharmacology 2:9, pages 1-7.
Crossref
Crossref
Stephen Cunningham, Emily Starr, Iain Shaw, John Glavin, Marian Kane & Lokesh Joshi. (2012) Development of a Convenient Competitive ELISA for the Detection of the Free and Protein-Bound Nonhuman Galactosyl-α-(1,3)-Galactose Epitope Based on Highly Specific Chicken Single-Chain Antibody Variable-Region Fragments. Analytical Chemistry 85:2, pages 949-955.
Crossref
Crossref
Haruki Hasegawa. (2013) Aggregates, Crystals, Gels, and Amyloids: Intracellular and Extracellular Phenotypes at the Crossroads of Immunoglobulin Physicochemical Property and Cell Physiology. International Journal of Cell Biology 2013, pages 1-22.
Crossref
Crossref
Rodney A. Prell, Donna W. Lee, Wendy G. Halpern & Anu V. Connor. 2013. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics
343
371
.
Peter N. Lipke, Melissa C. Garcia, David Alsteens, Caleen B. Ramsook, Stephen A. Klotz & Yves F. Dufr?ne. (2012) Strengthening relationships: amyloids create adhesion nanodomains in yeasts. Trends in Microbiology 20:2, pages 59-65.
Crossref
Crossref
Brian D. Harms, Jeffrey D. Kearns, Stephen V. Su, Neeraj Kohli, Ulrik B. Nielsen & Birgit Schoeberl. 2012. Protein Engineering for Therapeutics, Part A. Protein Engineering for Therapeutics, Part A
67
87
.